Unilife aims prefilled syringes at patients who self-inject

Last week, we mentioned Unilife, a York, PA-based developer of drug-delivery systems, is aiming its safety syringes at the market for healthcare workers increasingly concerned about needle-stick injuries. This week, Unilife announced its new line of auto-injectors are meant for the rising numbers of patients who inject themselves outside a healthcare setting.

Driving this market is the "development and commercial launch of biologics, biosimilar and other drugs suitable for patient self-injection as well as the enforcement of laws in the U.S., Europe and other emerging markets seeking to prevent needlestick injuries," according to a company statement.

Unilife says that its auto-injectors "enable patients to inject a fixed dose of medication with the simple push of a button, without ever seeing the needle."

"Conventional auto-injector technologies can cause some confusion among patients, as it can be difficult to determine just when the full dose has been delivered," Unilife CEO Alan Shortall said in a statement. "For Unifill Auto-Injectors, once a patient hears the audible-tactile indication signaling the activation of the safety mechanism, they know the dose has been fully administered and the device can be safely taken away from the body."

- read the release from Unilife

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.